Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, 10x Genomics's Enterprise Value is MXN23,412 Mil.
10x Genomics's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was MXN-3,052 Mil. Therefore, 10x Genomics's EV-to-EBIT ratio for today is -7.67.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, 10x Genomics's Enterprise Value is MXN23,412 Mil.
10x Genomics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was MXN-2,219 Mil. Therefore, 10x Genomics's EV-to-EBITDA ratio for today is -10.55.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, 10x Genomics's Enterprise Value is MXN23,412 Mil.
10x Genomics's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was MXN12,401 Mil. Therefore, 10x Genomics's EV-to-Revenue ratio for today is 1.89.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, 10x Genomics's Enterprise Value is MXN23,412 Mil.
10x Genomics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 was MXN882 Mil. Therefore, 10x Genomics's EV-to-FCF ratio for today is 26.53.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
10x Genomics Enterprise Value Historical Data
The historical data trend for 10x Genomics's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of 10x Genomics's Enterprise Value
For the Health Information Services subindustry, 10x Genomics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
10x Genomics's Enterprise Value Distribution in the Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, 10x Genomics's Enterprise Value distribution charts can be found below:
* The bar in red indicates where 10x Genomics's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
10x Genomics's Enterprise Value for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
10x Genomics (MEX:TXG) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
10x Genomics's current Enterprise Value is MXN23,412 Mil.
10x Genomics's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-3,052 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
10x Genomics's current Enterprise Value is MXN23,412 Mil.
10x Genomics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-2,219 Mil.
10x Genomics's current Enterprise Value is MXN23,412 Mil.
10x Genomics's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN12,401 Mil.
10x Genomics's current Enterprise Value is MXN23,412 Mil.
10x Genomics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN882 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
10x Genomics Enterprise Value Related Terms
Thank you for viewing the detailed overview of 10x Genomics's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MEX:TXG has been successfully added to your 